ASCO GU 2021 – News

March 15, 2021

Cabozantinib and nivolumab present clinical activity in the treatment of metastatic genitourinary tumors

Cabozantinib associated with nivolumab, as well as the combination of cabozantinib plus nivolumab and ipilimumab, showed promising efficacy and safety in a dose-escalation phase I trial in patients […]
March 2, 2021

Retroperitoneal lymph node dissection as an option in the 1st treatment line of the initial metastatic seminoma

Treatment is established for testicular germ cell tumors, but there are few data on its effectiveness as the first line in the treatment of phase II […]
March 2, 2021

ASCO GU 2021: Check out the analysis of the largest liquid biopsy trial for castration-resistant metastatic prostate cancer

The assessment of the genomic profiling (comprehensive genomic profiling, CGP) by NGS (next-generation sequencing) of circulating tumor DNA (ctDNA) provides a minimally invasive method for identifying […]
March 2, 2021

NAXIVA: The first trial of axitinib for treatment of renal cell carcinoma with venous tumor thrombus is highlighted in ASCO GU 2021

The extent of venous tumor thrombus (VTT) occurs in 4-15% of cases of renal cell carcinoma (RCC).  Mayo’s classification distinguishes four levels of VTT extension between […]
March 2, 2021

SWOG 1500 compares cabozantinib, crizotinib, or savolitinib versus sunitinib in the treatment of papillary renal carcinoma

MET signaling is a key molecular driver in the treatment of papillary renal carcinoma, however, treatment strategies in the metastatic setting are limited During the 2021 […]
February 23, 2021

Combination between HIF-2α inhibitor, MK-6482 and cabozantinib is highlighted in ASCO GU 2021

Belzutifan (MK-6482) is a HIF-2α inhibitor (hypoxia-inducible factor 2α), which showed favorable antitumor activity and safety as monotherapy, in a phase I trial of patients with […]
February 23, 2021

Precision medicine: genomic profile differences between penile and male urethral SCC

Although squamous cell carcinoma of the penis (pSCC) and male urethral epithelium (uSCC) appear in nearby localizations and may have similar histology, its clinical manifestations, disease […]
February 23, 2021

CheckMate 9KD: nivolumab plus docetaxel have promising activity in chemotherapy-naive metastatic castration-resistant prostate cancer

Docetaxel is standard chemotherapy for the treatment of mCRPC and may increase antitumor immune responses. Therefore, its use in combination with nivolumab could increase the benefit […]
February 23, 2021

68Ga-PSMA-11 PET/CT and multiparametric MRI in primary prostate cancer

Local staging of prostate cancer so far depends on systematic or directed biopsies by multiparametric magnetic resonance imaging (mpMRI). The role of PET PSMA in the […]